

# David Allen Schwartz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5758590/publications.pdf>

Version: 2024-02-01

75  
papers

3,106  
citations

159358

30  
h-index

161609

54  
g-index

78  
all docs

78  
docs citations

78  
times ranked

3354  
citing authors

#	ARTICLE	IF	CITATIONS
1	Demographic Factors Associated With Successful Telehealth Visits in Inflammatory Bowel Disease Patients. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 358-363.	0.9	12
2	Efficacy and Safety of 2 Vedolizumab Intravenous Regimens for Perianal Fistulizing Crohn's Disease: ENTERPRISE Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1059-1067.e9.	2.4	33
3	Health Care Costs and Resource Utilization Among Patients With Crohn's Disease With and Without Perianal Fistula. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 870-877.	0.9	11
4	Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 69-95.	3.7	41
5	A patient education intervention improved rates of successful video visits during rapid implementation of telehealth. <i>Journal of Telemedicine and Telecare</i> , 2021, , 1357633X2110087.	1.4	12
6	Endoscopic evaluation of surgically altered bowel in inflammatory bowel disease: a consensus guideline from the Global Interventional Inflammatory Bowel Disease Group. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 482-497.	3.7	28
7	Patterns of endoscopy during COVID-19 pandemic: a global survey of interventional inflammatory bowel disease practice. <i>Intestinal Research</i> , 2021, 19, 332-340.	1.0	8
8	Safety and Efficacy of Vedolizumab Versus Tumor Necrosis Factor $\pm$ Antagonists in an Elderly IBD Population: A Single Institution Retrospective Experience. <i>Digestive Diseases and Sciences</i> , 2021, , 1.	1.1	11
9	Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 826-849.	3.7	69
10	Inpatient Management of Inflammatory Bowel Disease-Related Complications. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1346-1355.	2.4	21
11	Assessing Severity of Disease in Patients with Ulcerative Colitis. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 671-688.	1.0	49
12	Gastroenterologist-Lead Management of Iron Deficiency Anemia in Inflammatory Bowel Disease Is Effective, Safe, and May Increase Quality of Life. <i>Crohn's &amp; Colitis 360</i> , 2020, 2, otaa051.	0.5	5
13	Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 393-405.	3.7	78
14	Precision nicotine metabolism-informed care for smoking cessation in Crohn's disease: A pilot study. <i>PLoS ONE</i> , 2020, 15, e0230656.	1.1	7
15	Prevalence of Fistulizing Crohn's Disease in the United States: Estimate From a Systematic Literature Review Attempt and Population-Based Database Analysis. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1773-1779.	0.9	53
16	Serum Polyunsaturated Fatty Acids Correlate with Serum Cytokines and Clinical Disease Activity in Crohn's Disease. <i>Scientific Reports</i> , 2019, 9, 2882.	1.6	41
17	Histoplasmosis as a Complication of Inflammatory Bowel Disease Therapy: A Case Series. <i>Inflammatory Bowel Diseases</i> , 2019, 25, e69-e70.	0.9	4
18	Role of interventional inflammatory bowel disease in the era of biologic therapy: a position statement from the Global Interventional IBD Group. <i>Gastrointestinal Endoscopy</i> , 2019, 89, 215-237.	0.5	61

#	ARTICLE	IF	CITATIONS
19	Management of Pouchitis and Other Common Complications of the Pouch. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 989-996.	0.9	61
20	Alterations in lipid, amino acid, and energy metabolism distinguish Crohn's disease from ulcerative colitis and control subjects by serum metabolomic profiling. <i>Metabolomics</i> , 2018, 14, 17.	1.4	137
21	Challenges in Using Real-world Clinical Practice Records for Validation of Clinical Trial Data in Inflammatory Bowel Disease: Lessons Learned. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2-4.	0.9	4
22	Adherence rates and health care costs in Crohn's disease patients receiving certolizumab pegol with and without home health nurse assistance: results from a retrospective analysis of patient claims and home health nurse data. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 869-878.	0.8	7
23	White Paper AGA: The Impact of Mental and Psychosocial Factors on the Care of Patients With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 986-997.	2.4	83
24	Current management of perianal Crohn's disease. <i>Current Problems in Surgery</i> , 2017, 54, 262-298.	0.6	9
25	Depressive Symptoms Predict Anti-tumor Necrosis Factor Therapy Noncompliance in Patients with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2017, 62, 3563-3567.	1.1	23
26	Comparison of Health Care Utilization and Costs Between Patients with Perianal Fistulizing Crohn's Disease Treated with Biologics with or Without Previous Seton Placement. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1860-1866.	0.9	15
27	Endoscopy in inflammatory bowel disease: advances in disease management. <i>Gastrointestinal Endoscopy</i> , 2017, 86, 952-961.	0.5	5
28	Clinical characterization of in vivo inflammatory bowel disease with Raman spectroscopy. <i>Biomedical Optics Express</i> , 2017, 8, 524.	1.5	41
29	Serum Fatty Acids Are Correlated with Inflammatory Cytokines in Ulcerative Colitis. <i>PLoS ONE</i> , 2016, 11, e0156387.	1.1	51
30	Association Between Affective-Cognitive Symptoms of Depression and Exacerbation of Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2016, 111, 864-870.	0.2	50
31	The Gastroenterologist's Role in Management of Perianal Fistula. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2016, 26, 693-705.	0.6	6
32	Colestipol granules in the colon: macroscopic and microscopic findings. <i>Histopathology</i> , 2015, 67, 141-142.	1.6	4
33	Cumulative Evidence That Mesenchymal Stem Cells Promote Healing of Perianal Fistulas of Patients With Crohn's Disease—Going From Bench to Bedside. <i>Gastroenterology</i> , 2015, 149, 853-857.	0.6	22
34	Outcomes Following Infliximab Therapy for Pediatric Patients Hospitalized With Refractory Colitis—Predominant IBD. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2014, 58, 213-219.	0.9	21
35	Identification of pathologic features associated with "ulcerative colitis-like" Crohn's disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 13139.	1.4	13
36	MTG16 contributes to colonic epithelial integrity in experimental colitis. <i>Gut</i> , 2013, 62, 1446-1455.	6.1	22

#	ARTICLE	IF	CITATIONS
37	High-Throughput Multi-Analyte Luminex Profiling Implicates Eotaxin-1 in Ulcerative Colitis. PLoS ONE, 2013, 8, e82300.	1.1	51
38	15-Year-Old Girl With Metaplastic Atrophic Gastritis and Enterochromaffin-Like Cell Hyperplasia. Journal of Pediatric Gastroenterology and Nutrition, 2012, 55, e148-51.	0.9	3
39	Perianal Crohn's Disease—A Gastroenterologist's Perspective. Seminars in Colon and Rectal Surgery, 2012, 23, 117-124.	0.2	1
40	The Evaluation and Treatment of Crohn Perianal Fistulae: EUA, EUS, MRI, and Other Imaging Modalities. Gastroenterology Clinics of North America, 2012, 41, 379-391.	1.0	35
41	Managing Perianal Crohn's Disease. Current Gastroenterology Reports, 2012, 14, 153-161.	1.1	20
42	Proteomic profiling of mucosal and submucosal colonic tissues yields protein signatures that differentiate the inflammatory colitides. Inflammatory Bowel Diseases, 2011, 17, 875-883.	0.9	59
43	Increased serum levels of L-arginine in ulcerative colitis and correlation with disease severity. Inflammatory Bowel Diseases, 2010, 16, 105-111.	0.9	35
44	Endoscopic ultrasound to guide the combined medical and surgical management of pediatric perianal Crohn's disease. Inflammatory Bowel Diseases, 2010, 16, 461-468.	0.9	41
45	Increased expression and cellular localization of spermine oxidase in ulcerative colitis and relationship to disease activity. Inflammatory Bowel Diseases, 2010, 16, 1557-1566.	0.9	40
46	Treatment of Fistulizing Inflammatory Bowel Disease. Medical Clinics of North America, 2010, 94, 19-34.	1.1	8
47	A 31-Year-Old Patient With Colitis and Perianal Disease. Clinical Gastroenterology and Hepatology, 2010, 8, 10-14.	2.4	3
48	Imaging and the Treatment of Crohn's Perianal Fistulas. American Journal of Gastroenterology, 2009, 104, 2987-2989.	0.2	17
49	Survey of gastroenterologists' awareness and implementation of AGA guidelines on osteoporosis in inflammatory bowel disease patients: Are the guidelines being used and what are the barriers to their use?. Inflammatory Bowel Diseases, 2009, 15, 1082-1089.	0.9	41
50	Treatment of Fistulizing Inflammatory Bowel Disease. Gastroenterology Clinics of North America, 2009, 38, 595-610.	1.0	18
51	Prevalence and Outcome of Anemia After Restorative Proctocolectomy. Diseases of the Colon and Rectum, 2009, 52, 726-739.	0.7	32
52	Endoscopic Ultrasound and Computed Tomography Predictors of Pancreatic Cancer Resectability. Journal of Gastrointestinal Surgery, 2008, 12, 10-16.	0.9	41
53	To lap or not to lap, that is the question—no longer?. Inflammatory Bowel Diseases, 2008, 14, 1161-1162.	0.9	1
54	What is the optimal maintenance treatment for perianal Crohn's disease?. Inflammatory Bowel Diseases, 2008, 14, S269-S270.	0.9	2

#	ARTICLE	IF	CITATIONS
55	A Randomized Prospective Trial of Endoscopic Ultrasound to Guide Combination Medical and Surgical Treatment for Crohn's Perianal Fistulas. <i>American Journal of Gastroenterology</i> , 2008, 103, 2527-2535.	0.2	92
56	The PRECiSE 2 trial of certolizumab pegol, a new PEGylated anti-TNF agent, in the treatment of Crohn's disease: An interview with David A Schwartz, 13 June 2007. <i>Biologics: Targets and Therapy</i> , 2008, 2, 126-8.	3.0	3
57	Nasal Crohn's disease /apheresis. <i>Gastroenterology and Hepatology</i> , 2008, 4, 127-8.	0.2	0
58	Metastatic signet-ring carcinoma of the colon diagnosed by EUS-guided FNA in a patient with Crohn's disease. <i>Gastrointestinal Endoscopy</i> , 2007, 65, 945-947.	0.5	3
59	Small Bowel Adenocarcinoma Complicating Crohn's Disease: Case Series and Review of the Literature. <i>American Surgeon</i> , 2007, 73, 1181-1187.	0.4	51
60	Evolution of the restorative proctocolectomy and its effects on gastrointestinal hormones. <i>International Journal of Colorectal Disease</i> , 2007, 22, 1143-1163.	1.0	17
61	Treatment of perianal fistula and abscess: Crohn's and non-Crohn's. <i>Current Treatment Options in Gastroenterology</i> , 2007, 10, 211-220.	0.3	12
62	Management of Perianal Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 426-430.	2.4	28
63	Urine PGE-M: A Metabolite of Prostaglandin E2 as a Potential Biomarker of Advanced Colorectal Neoplasia. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 1358-1365.	2.4	74
64	Pilot Feasibility Studies of Leukocytapheresis With the Adacolumn Apheresis System in Patients With Active Ulcerative Colitis or Crohn Disease. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, 482-489.	1.1	32
65	Endoscopic Ultrasound Diagnosis of Pelvic Lipoma Causing Neurologic Symptoms. <i>Digestive Diseases and Sciences</i> , 2006, 51, 1364-1366.	1.1	7
66	The Successful Use of Adalimumab to Treat Active Crohn's Disease of an Ileoanal Pouch During Pregnancy. <i>Digestive Diseases and Sciences</i> , 2006, 51, 2045-2047.	1.1	85
67	Successful Paternity of a Healthy Child While Taking Methotrexate for Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2006, 101, 2893-2894.	0.2	7
68	Looking in the Rear View Mirror at Pentasa in Active Crohn's Disease: Results May Be Smaller Than They First Appear. <i>Inflammatory Bowel Diseases</i> , 2005, 11, 73-74.	0.9	1
69	Calcaneal Ultrasound Bone Densitometry Is Not a Useful Tool to Screen Patients With Inflammatory Bowel Disease at High Risk for Metabolic Bone Disease. <i>Inflammatory Bowel Diseases</i> , 2005, 11, 749-754.	0.9	9
70	Use of Endoscopic Ultrasound to Guide Combination Medical and Surgical Therapy for Patients With Crohn's Perianal Fistulas. <i>Inflammatory Bowel Diseases</i> , 2005, 11, 727-732.	0.9	102
71	The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. <i>Gastroenterology</i> , 2002, 122, 875-880.	0.6	984
72	Endoscopic ultrasound techniques for pancreatic cystic neoplasms. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2002, 12, 709-718.	0.6	4

#	ARTICLE	IF	CITATIONS
73	The role of endoscopic ultrasound in hepatobiliary disease. Current Gastroenterology Reports, 2002, 4, 72-78.	1.1	10
74	The rate of false-positive results with EUS-guided fine-needle aspiration. Gastrointestinal Endoscopy, 2002, 56, 868-872.	0.5	19
75	Tofacitinib Adherence and Outcomes in Refractory Inflammatory Bowel Disease. Crohn's & Colitis 360, 0, , .	0.5	0